Barclays analyst Gena Wang raised the firm’s price target on Cellectis (CLLS) to $8 from $4 and keeps an Overweight rating on the shares. The company’s research and development day provided updates on lasme-cel’s “promising” efficacy data, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLLS: